Price Over Earnings Overview: Insulet - Insulet ( NASDAQ:PODD )
Looking into the current session, Insulet Inc. ( NASDAQ:PODD ) shares are trading at $306.78, after a 1.24% drop. Over the past month, the stock fell by 11.06%, but over the past year, it actually spiked by 31.87%.
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet ( NASDAQ: PODD ) has outperformed the market over the past 15 years by 10.02% on an annualized basis producing an average annual return of 22.35%. Currently, Insulet has a market capitalization of $21.87 billion.
Why Insulet ( PODD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Here's How Much $100 Invested In Insulet 10 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 10 years by 14.5% on an annualized basis producing an average annual return of 27.65%. Currently, Insulet has a market capitalization of $23.29 billion.
Spotlight on DexCom: Analyzing the Surge in Options Activity - DexCom ( NASDAQ:DXCM )
Deep-pocketed investors have adopted a bearish approach towards DexCom DXCM, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.
Here's Why Insulet ( PODD ) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Insulet ( PODD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 11.51% on an annualized basis producing an average annual return of 23.94%. Currently, Insulet has a market capitalization of $24.22 billion.
Here's Why Insulet ( PODD ) is a Strong Growth Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Insulet ( PODD ) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Insulet Gains 77.2% in a Year: What's Driving the Rally?
PODD's 77.2% stock surge is fueled by Omnipod 5 expansion, global launches, strong Q2 profits and robust financial stability.
Cisco, Rocket Companies, Insulet And More On CNBC's 'Final Trades' - Cisco Systems ( NASDAQ:CSCO ) , iShares Expanded Tech-Software Sector ETF ( BATS:IGV )
Liz Young Thomas said iShares Expanded Tech-Software Sector ETF ( NYSE: IGV ) is way under-loved. Jim Lebenthal says Cisco pulled back around 8% after earnings. Get more market-moving news first with AI-powered analysis that turns noise into opportunity.
Here's How Much You Would Have Made Owning Insulet Stock In The Last 15 Years - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 10.41% on an annualized basis producing an average annual return of 23.21%. Currently, Insulet has a market capitalization of $22.62 billion.
Is the Market Bullish or Bearish on Insulet? - Insulet ( NASDAQ:PODD )
Insulet's PODD short percent of float has fallen 17.43% since its last report. The company recently reported that it has 1.75 million shares sold short, which is 3.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.58 days to cover their ...
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise
PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.
Why Insulet ( PODD ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5 - Insulet ( NASDAQ:PODD )
Q2 revenue rises 32.9% Y/Y to $649.1 million, beating estimates and topping guidance range. Insulet raises FY25 sales outlook to $2.57 billion-$2.63 billion, above prior view of $2.47 billion-$2.53 billion. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
Applovin, Sunrun, Duolingo, Tutor Perini, Installed Building Products And Other Big Stocks Moving Higher On Thursday - AppLovin ( NASDAQ:APP ) , Advanced Micro Devices ( NASDAQ:AMD )
U.S. stocks were mixed, with the Dow Jones index falling around 200 points on Thursday. Shares of Applovin Corp APP rose sharply during Thursday's session following upbeat earnings. AppLovin reported second-quarter revenue of $1.26 billion, missing analyst estimates of $1.31 billion, according ...
Insulet ( PODD ) Q2 Revenue Jumps 33%
Insulet ( NASDAQ:PODD ) , a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong outperformance: GAAP revenue rose to $649.1 million, beating estimates by nearly $35 million, while ...
Insulet ( PODD ) Surpasses Q2 Earnings and Revenue Estimates
Insulet (PODD) delivered earnings and revenue surprises of +25.81% and +5.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Curious about Insulet ( PODD ) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Here's How Much You Would Have Made Owning Insulet Stock In The Last 10 Years - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 10 years by 12.07% on an annualized basis producing an average annual return of 23.62%. Currently, Insulet has a market capitalization of $20.05 billion.
Insulet ( PODD ) Reports Next Week: Wall Street Expects Earnings Growth
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Looking Into Insulet's Recent Short Interest - Insulet ( NASDAQ:PODD )
Insulet's PODD short percent of float has risen 16.26% since its last report. The company recently reported that it has 2.21 million shares sold short, which is 4.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.61 days to cover their ...
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 10 years by 12.88% on an annualized basis producing an average annual return of 24.39%. Currently, Insulet has a market capitalization of $19.95 billion.
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes - Eli Lilly ( NYSE:LLY ) , DexCom ( NASDAQ:DXCM )
In a public post in May, I wrote about Sana Biotechnology, Inc. SANA, a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since. Functional-cure potential. Sana's hypo-immune ( HIP ) edits let donor islet cells make insulin without triggering ...
Check Out What Whales Are Doing With DXCM - DexCom ( NASDAQ:DXCM )
Investors with a lot of money to spend have taken a bearish stance on DexCom DXCM. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Will Insulet ( PODD ) Beat Estimates Again in Its Next Earnings Report?
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - AeroVironment ( NASDAQ:AVAV ) , Dyne Therapeutics ( NASDAQ:DYN )
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Tesla, Inc. TSLA fell sharply in pre-market trading after CEO Elon Musk reignited political comeback rumors following his criticism of President Donald Trump's spending bill.
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 9.72% on an annualized basis producing an average annual return of 22.42%. Currently, Insulet has a market capitalization of $21.04 billion.
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global ...
PTC Unveils Arena SCI for Resilient Product Development
PTC debuts Arena SCI to tackle supply chain risk with AI, even as mounting debt highlights growing financial pressure.
Here's Why You Should Retain PODD Stock in Your Portfolio Now
Insulet's Omnipod 5 gains traction with global expansion and rising Type 2 adoption despite economic and competitive hurdles.
$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 10.29% on an annualized basis producing an average annual return of 22.12%. Currently, Insulet has a market capitalization of $21.56 billion.
S&P 500 Wraps Up Best May Since 1990: 5 Top Stocks in the ETF
SPY jumped 6.3% in May, the most in decades, led by standout gains in NRG, STX, CEG, PODD and MCHP amid easing trade fears.
Goldman Sachs Bullish On Dexcom And Insulet As Diabetes Tech Surges - Beta Bionics ( NASDAQ:BBNX ) , Insulet ( NASDAQ:PODD ) , DexCom ( NASDAQ:DXCM )
Goldman sets $380 target for Insulet, citing Omnipod's unique design and share capture potential. Dexcom gets $104 target, expected to gain share in non-insulin diabetes segments through 2025. Rebound or breakdown? See how Matt Maley is trading June's market volatility, live this Wednesday, June ...
Here's How Much $100 Invested In Insulet 15 Years Ago Would Be Worth Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 10.91% on an annualized basis producing an average annual return of 22.7%. Currently, Insulet has a market capitalization of $22.82 billion.
Insulet Gains 78.5% in a Year: What's Driving the Stock?
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies
Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies are part of the Zacks Industry Outlook article.
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
The End Of The Diabetes Industry? - Eli Lilly ( NYSE:LLY ) , DexCom ( NASDAQ:DXCM )
Years ago, in a conversation with an endocrinologist, I mentioned there was no incentive to cure diabetes, giving the money companies were making from managing it ( with testing supplies, insulin, etc. ) . He replied that the incumbents had no incentive to cure it, but a startup company would.
$1000 Invested In Insulet 15 Years Ago Would Be Worth This Much Today - Insulet ( NASDAQ:PODD )
Insulet PODD has outperformed the market over the past 15 years by 10.99% on an annualized basis producing an average annual return of 22.69%. Currently, Insulet has a market capitalization of $22.63 billion.
Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised
PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.
Insulet Posts Upbeat Earnings, Joins Trade Desk, TransMedics Group, Tesla And Other Big Stocks Moving Higher On Friday - Definitive Healthcare ( NASDAQ:DH ) , AvePoint ( NASDAQ:AVPT )
U.S. stocks were higher, with the Nasdaq Composite gaining around 100 points on Friday. Shares of Insulet Corporation PODD rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance above estimates.
Insulet ( PODD ) Q1 Earnings and Revenues Surpass Estimates
Insulet (PODD) delivered earnings and revenue surprises of 25.93% and 4.96%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Curious about Insulet ( PODD ) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.
This Saia Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday - Icon ( NASDAQ:ICLR ) , Insulet ( NASDAQ:PODD )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
